Testing a new RSV treatment for hospitalized babies
Part of Infections, Lungs & breathing clinical trials.
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is between 1 month and 24 months old (adjusted for premature birth).
- They have a confirmed RSV infection diagnosed within the last 36 hours.
- Symptoms started less than 5 days ago.
- They weigh at least 2.5 kg (5.5 pounds) and no more than 20 kg (44 pounds).
- They have a moderate to severe breathing difficulty scored by the doctor.
- They haven't taken certain antiviral or steroid medicines recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
This trial tests if an inhaled interferon solution can help children under 2 years old with a moderate to severe RSV lung infection. It aims to reduce symptoms like cough and trouble breathing.
This trial tests if antiviral medications can help adults with early respiratory syncytial virus (RSV) feel better faster. It is for people aged 18 to 64 who have had RSV symptoms for 4 days or less and have tested positive for the virus.
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
This trial is testing a new medicine called deuremidevir for babies and young children with RSV infection. It is for those who have symptoms like fast breathing and wheezing, and have been sick for no more than 96 hours.
Hear when a new Respiratory Synctial Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.